|
Barrie Carter, Ph.D. has been the Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation since 1992. Previously, he was at the National Institutes of Health (NIH) for 22 years serving as Chief of the Laboratory of Molecular and Cellular Biology in the National Institute for Diabetes and Digestive and Kidney Diseases from 1982 to 1992. Prior to joining the NIH, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. He received his B.Sc. with Honors from the University of Otago, Dunedin, New Zealand and his Ph.D. in the Biochemistry Department of the University of Otago Medical School. Dr. Carter's long-term research interests are in the molecular biology of viruses, development of AAV vectors and gene therapy. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology. From 1995-2000 Dr. Carter was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter currently serves as a member of the Advisory Committee to the Director, NIH and is a member of the Board of Directors of the American Society for Gene Therapy.
| 